Bendamustine in indolent lymphoma: Letting the dust settle down.

In a large population‐based cohort of patients with indolent B‐cell lymphoma, bendamustine–rituximab was not associated with a statistically significant excess risk of secondary primary malignancies compared with cyclophosphamide‐based regimens after adjustment for confounders. These data contextualize prior safety concerns and support thoughtful optimization rather than abandonment of bendamustine‐based frontline therapies in indolent B‐cell lymphomas.